777 Old Saw Mill River Road
Tarrytown, NY 10591
Contact: Delman Lebel, Associate Director of State Public Policy and Government Affairs
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to consistently translate science into medicine has led to numerous FDA-approved treatments and over fifteen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
Fully human monoclonal antibodies: Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.
Fusion proteins: Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.
Regeneron Genetics Center: A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.
Stock Symbol: REGN
World Employees: 5,500